Immunai
Tel Aviv, Israel· Est.
Immunai leverages AI‑powered single‑cell multi‑omics to accelerate immune‑focused drug discovery and development.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $45M
AI Company Overview
Immunai leverages AI‑powered single‑cell multi‑omics to accelerate immune‑focused drug discovery and development.
OncologyImmunologyInflammatory
Technology Platform
AI‑driven single‑cell multi‑omics platform that integrates the AMICA immune cell atlas and the Immunodynamics machine‑learning engine to generate actionable therapeutic insights.
Opportunities
Scaling the platform to additional therapeutic areas and offering SaaS analytics to pharma R&D teams will drive recurring revenue and broaden market reach.
Risk Factors
Reliance on a few large pharma partners and regulatory constraints on patient data could limit growth if partnerships falter or data‑privacy laws tighten.
Competitive Landscape
Immunai competes with AI‑driven biotech firms such as GNS Healthcare and Tempus, but differentiates through its immune‑focused single‑cell multi‑omics integration and transparent recommendation engine.